News: Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

66.06USD
24 Oct 2014
Price Change (% chg)

$1.71 (+2.66%)
Prev Close
$64.35
Open
$64.58
Day's High
$66.23
Day's Low
$64.41
Volume
632,694
Avg. Vol
978,579
52-wk High
$67.12
52-wk Low
$48.89

Search Stocks
Select another date:

Thu, Oct 23 2014

Photo

Lilly profit plunges as cheaper generics take toll

- Eli Lilly and Co said its quarterly earnings plunged 58 percent, hurt by special charges and generic competition for its Cymbalta depression drug, but it affirmed its full-year profit forecast.

Stada secures third license for copycat biotech drug: CEO

BAD VILBEL Germany - Germany's Stada plans to bring a copy of Eli Lilly's Forteo osteoporosis treatment to market, its chief executive said, as the generic drugmaker moves further into the sale of cheaper alternatives for costly biotech drugs.

EU mergers and takeovers (Oct 3)

BRUSSELS, Oct 3 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

EU Commission clears Eli Lilly, Novartis deal

BRUSSELS - EU antitrust regulators approved U.S. drugmaker Eli Lilly's $5.4 billion takeover of Swiss peer Novartis's animal health business on Friday.

EU Commission clears Eli Lilly-Novartis animal health deal

BRUSSELS, Oct 3 - EU antitrust regulators approved U.S. drugmaker Eli Lilly's $5.4 billion takeover of Swiss peer Novartis's animal health business on Friday.

EU to extend Zimmer, Biomet probe, clear Eli Lilly, Novartis deal: sources

BRUSSELS - EU antitrust regulators will open an extensive probe into Zimmer's $13.4 billion bid for Biomet, concerned that the creation of the world's second-largest orthopedic products group may hurt competition, three people familiar with the matter said on Thursday.

UPDATE 2-EU to extend Zimmer, Biomet probe, clear Eli Lilly, Novartis deal - sources

* Zimmer may have to offer concessions to allay EU worries

Eli Lilly stops development of lupus drug; XTL shares soar

- Eli Lilly and Co said it would stop the development of its drug to treat the autoimmune disorder lupus, after it was found to be not effective enough in late-stage trials.

EU to extend Zimmer, Biomet probe, clear Eli Lilly, Novartis deal - sources

BRUSSELS, Oct 2 - EU antitrust regulators will widen a probe into Zimmer Holdings Inc's $13.4 billion bid for Biomet Inc but clear Eli Lilly's offer for a Novartis AG unit, three people familiar with the matter said on Thursday.

Eli Lilly to drop development of lupus drug

Oct 2 - Eli Lilly and Co said it would discontinue the development of its lupus drug as the treatment was not found to be effective enough in two late-stage trials.

Select another date:
Search Stocks